CFTR and cystic fibrosis: We evaluated Symdeko, a CF drug consisting of VX-661 combined with VX-770, which has been approved for patients homozygous for F508del as well as for other genotypes, including partial function CFTR mutations (Rowe et al., 2017; Taylor-Cousar et al., 2017; Donaldson et al., 2018).